TrustInSoft has developed a source code analysis tool known as TrustInSoft Analyzer, which meticulously evaluates C and C++ code, providing mathematical assurances that defects are absent, software components are shielded from prevalent security vulnerabilities, and the code adheres to specified requirements. This innovative technology has gained recognition from the National Institute of Standards and Technology (NIST), marking it as the first globally to fulfill NIST’s SATE V Ockham Criteria, which underscores the significance of high-quality software.
What sets TrustInSoft Analyzer apart is its implementation of formal methods—mathematical techniques that facilitate a comprehensive examination to uncover all potential vulnerabilities or runtime errors while ensuring that only genuine issues are flagged.
Organizations utilizing TrustInSoft Analyzer have reported a significant reduction in verification expenses by 4 times, a 40% decrease in the efforts dedicated to bug detection, and they receive undeniable evidence that their software is both secure and reliable.
In addition to the tool itself, TrustInSoft’s team of experts is ready to provide clients with training, ongoing support, and various supplementary services to enhance their software development processes. Furthermore, this comprehensive approach not only improves software quality but also fosters a culture of security awareness within organizations.
Learn more
Jama Connect® is an innovative platform for product development that establishes Living Requirements™. It weaves together disparate activities related to testing and risk management, ensuring comprehensive compliance, mitigating potential risks, enhancing processes, and maintaining adherence to regulations. Organizations involved in developing intricate products, systems, and software can now effectively outline, synchronize, and implement their requirements. This streamlined approach significantly decreases the time and resources needed to demonstrate compliance and minimizes the need for rework. By selecting a user-friendly, adaptable solution accompanied by supportive services focused on fostering adoption, companies can confidently pave the way to their success. The platform’s design emphasizes collaboration, ensuring that all stakeholders are aligned throughout the product development lifecycle.
Learn more
Genedata Biologics
Genedata Biologics® significantly advances the creation of biotherapeutics such as bispecifics, ADCs, TCRs, CAR-Ts, and AAVs, offering an all-encompassing solution for the sector. Esteemed as a premier platform in its domain, it seamlessly integrates all discovery processes, empowering researchers to focus on true innovation. By employing a cutting-edge system specifically designed to digitize the biotherapeutic discovery journey, research timelines can be notably expedited. This platform streamlines complex R&D activities by aiding in the design, tracking, testing, and evaluation of new biotherapeutic entities. It accommodates a variety of formats, including antibodies, bi- or multi-specifics, ADCs, novel scaffolds, and therapeutic proteins, along with engineered therapeutic cell lines like TCRs and CAR-T cells. As a fully integrated data backbone, Genedata Biologics links all R&D activities, from library design and immunization to selection and panning, molecular biology, screening, protein engineering, expression, purification, and analytics, resulting in thorough evaluations of candidate developability and manufacturability. This comprehensive integration not only enables researchers to make well-informed choices but also fosters a culture of exploration and advancement in biotherapeutic innovation. Ultimately, the synergy of these capabilities positions Genedata Biologics as a vital asset in the competitive landscape of biopharmaceutical development.
Learn more
Gritstone
At the core of our immunotherapy strategy is our deep understanding of antigens and neoantigens, especially when it comes to pinpointing which variations will be transcribed, translated, processed, and ultimately presented on cell surfaces through Human leukocyte antigen (HLA) molecules, making them identifiable to T cells. We utilize Gritstone EDGETM, an innovative platform that leverages machine learning to facilitate this process. The development of cancer immunotherapies that target tumor-specific neoantigens is particularly challenging due to the multitude of mutations present in tumors, where only a select few translate into true tumor-specific neoantigens. To address this intricate issue, we have engineered EDGE's advanced integrated neural network model, which has been trained on millions of data points sourced from a wide array of tumor and normal tissue samples derived from various patient backgrounds. This comprehensive training significantly boosts our ability to accurately identify neoantigens and enhances the overall effectiveness of our immunotherapy approaches, ultimately aiming to provide more targeted and effective treatments for patients. By continually refining our methods and expanding our databases, we strive to stay at the forefront of cancer immunotherapy advancements.
Learn more
